Mouse Anti-GPRC5D Recombinant Antibody (5B7) (V2LY-0226-LY903)

Name: Mouse Anti-GPRC5D Recombinant Antibody (5B7)
SKU: V2LY-0226-LY903
Rating: 5 (1 reviews)

See all GPRC5D antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

5B7

Application

ELISA, IP, IF, WB

Immunogen

Amino acids 7-24 within an extracellular domain of mouse GPRC5D.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG1, κ

Clonality

Monoclonal

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, gelatin

Preservative

Sodium azide

Concentration

0.2 mg/ml

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

G protein-coupled receptor class C group 5 member D

Entrez Gene ID

55507

UniProt ID

Q9NZD1

Cellular Location

Cell membrane

Topology

Extracellular: 1-27
Helical: 28-48
Cytoplasmic: 49-63
Helical: 64-84
Extracellular: 85-93
Helical: 94-114
Cytoplasmic: 115-123
Helical: 124-144
Extracellular: 145-167
Helical: 168-188
Cytoplasmic: 189-204
Helical: 205-225
Extracellular: 226-239
Helical: 240-260
Cytoplasmic: 261-345

Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., ... & Huang, H. (2023). GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology, 10(2), e107-e116.

Nath, K., Costa, B. A., & Mailankody, S. (2023). GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nature Reviews Clinical Oncology, 1-2.

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., ... & Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387(13), 1196-1206.

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., ... & Krishnan, A. (2022). Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine, 387(24), 2232-2244.

Berdeja, J. G., Krishnan, A. Y., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., Askari, E., ... & Chari, A. (2021). Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., ... & Smith, E. L. (2021). Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Blood, 138, 827.

Chari, A., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodriguez, P., Askari, E., ... & Krishnan, A. (2020). A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood, 136, 40-41.

Fernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., ... & Smith, E. L. (2020). Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaAddressing BCMA Escape with Dual-Targeted CAR T-cell Therapy. Blood Cancer Discovery, 1(2), 146-154.

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., ... & Brentjens, R. J. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science translational medicine, 11(485), eaau7746.

Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., ... & Akashi, K. (2019). Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple MyelomaAnti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody. Molecular cancer therapeutics, 18(9), 1555-1564.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-GPRC5D Recombinant Antibody (5B7)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Human Recombinant GPRC5D-VLP protein, Fluorescent Conjugated, (CAT#: V2LY-0526-LY4400)

Mouse Anti-GPRC5D Recombinant Antibody (CBFYH-0465) (CAT#: CBMAB-H1336-FY)

Human Recombinant GPRC5D, Nanodisc protein, Biotin Conjugated, His Tag (CAT#: V2LY-0526-LY4399)

Human Anti-GPRC5D Recombinant Antibody (CBLG1-1652) (CAT#: CBMAB-G4690-LY)

Human Anti-GPRC5D Recombinant Antibody (
3D4) (CAT#: V2LY-0725-LY1431)

Mouse Anti-GPRC5D Recombinant Antibody (CBLG1-207) (CAT#: V2LY-0226-LY924)

Human Recombinant GPRC5D-VLP protein (CAT#: V2LY-0526-LY189)

Human Anti-GPRC5D Recombinant Antibody (CBLG1-1653) (CAT#: V2LY-0226-LY928)

Mouse Recombinant GPRC5D (Nanodisc) protein, His Tag (CAT#: V2LY-0526-LY8373)

Mouse Anti-GPRC5D Recombinant Antibody (CBLG1-3204) (CAT#: CBMAB-G4689-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry